GlaxoSmithKline plc (GSK.L)
LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,419.00+1.20 (+0.08%)
As of 11:16AM BST. Market open.
| Previous close | 1,417.80 |
| Open | 1,405.60 |
| Bid | 1,418.60 x 0 |
| Ask | 1,419.20 x 0 |
| Day's range | 1,413.00 - 1,425.00 |
| 52-week range | 1,190.80 - 1,619.20 |
| Volume | 1,145,569 |
| Avg. volume | 7,968,023 |
| Market cap | 71.4B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 16.35 |
| EPS (TTM) | 86.80 |
| Earnings date | 27 Oct 2021 |
| Forward dividend & yield | 0.80 (5.64%) |
| Ex-dividend date | 19 Aug 2021 |
| 1y target est | 1,644.50 |
- Yahoo Finance Video
Doctor on Delta variant: ’All of us are extremely concerned’
Dr. Michael Gonzalez, Emergency Medicine Physician & Assistant Professor at Baylor College of Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
- Zacks
Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.
- Business Wire
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
LONDON, July 29, 2021--GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps.
© 2021 Verizon Media. All rights reserved.
